Page results
-
Our nationally-recognised service helps children and young people (up to 19 years) with type 1 diabetes, type 2 diabetes, monogenic diabetes such as maturity onset diabetes in the young (MODY) and steroid related diabetes.
-
UCLH patient information for using Control IQ technology
-
This service is part of Respond. We offer general paediatric clinic appointments at UCLH to children and young people seeking asylum and refugees. Children are seen by a dedicated team of paediatricians with expertise in asylum seeker and refugee healthcare, and trauma-informed care. This includes unaccompanied children seeking asylum-seeking children (UASC), in partnership with local children looked after health services.
-
Dr Nagendran is a consultant neurophysiologist eripheral nerve and muscle disease, skeletal muscle channelopathies, nerve excitability disorders
-
UCLH is a specialist centre for the treatment of urological cancers.
-
This page is for parents and carers of children with sickle cell disease. It explains what happens during a Transcranial Doppler Scan.
-
This page is about the leukaemia multidisciplinary team (MDT) and how they can help you through your treatment.
-
Between April 2021 and March 2022, 40% of UCLH outpatient appointments took place virtually - a total of 484,872 appointments – the highest in England.
-
Information about sickle cell disorder in adulthood for UCLH patients.
-
Patient information for patients undergoing the removal of bot/tumbu flies and jigger fleas.
File results
-
FOI/2023/0550 - Varicose veins referrals, treatment and wait time
-
FOI/2023/0553 - Maternity complaints by ethnicity
-
FOI/2023/0559 - Patients admitted to hospital with dental distress
-
FOI/2023/0560 - Digital maternity training platform
-
FOI/2023/0561 - Birthrate Plus
-
FOI/2023/0563 - Treatment for Haemophilia B and Von Willebrand disease
-
FOI/2023/0565 - Rare diseases - diagnosis/ treatment for Fabry/ Gaucher/ Pompe
-
FOI/2023/0566 - Structure chart for IM &T, Business Intelligence, Informatics
-
FOI/2023/0569 - Treatment for Ruxolitinib
-
FOI/2023/0578 - Spinal Muscular Atrophy (SMA) patients